Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Augustine secures $85m to advance Charcot-Marie-Tooth candidate [Yahoo! Finance]
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Tenaya Therapeutics, Inc. (TNYA) Stock [Seeking Alpha]